Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

Industry Professionals: MDS Tardive Dyskinesia Virtual Course

CME Credits:0Date:Nov 24, 2021 - Dec 10, 2021

Foundational / Beginner

Program Description

The MDS Tardive Dyskinesia Virtual Course for Industry Professionals will comprise of three lectures that will review phenomenology (with video), important differential diagnosis, epidemiology, pathophysiology and evidence-based treatment guideline based on recent trials.

Although the second generation of antipsychotic drugs may have reduced the incidence of tardive disorders in schizophrenia, their increased use for non-psychotic indications has increased our need to better recognize and treat these problems. The recent development of medications to treat tardive disorders has altered our treatment algorithms.


  • Other Movement Disorders
  • Parkinson Disease/Hypokinetic Movement Disorders


Course Director
Roongroj Bhidayasiri, MD, FRCP - Chulalongkorn Centre of Excellence on Parkinson's Disease & Related Disorders, Bangkok, Thailand

Karen Frei, MD - Loma Linda University Medical Center, Loma Linda, CA, USA
Joseph Jankovic, MD - Baylor College of Medicine, Houston, TX, USA

Course Purpose

The primary purpose of this program is to review phenomenology, important differential diagnosis, epidemiology, pathophysiology and evidence-based treatment guideline based on recent trials of tardive dyskinesia.

Lectures will be available for on-demand viewing beginning on November 24, 2021 until December 31, 2021.

Registration Fees
Members: $75 USD
Non-Members: $75 USD

To view the course schedule please click 'PROCEED TO COURSE'.

Learning Objectives

Upon completion of this activity learners will be able to:
1. Provide guidance on how to recognise tardive dyskinesia, its risk factors, burden on patients, and how to distinguish it from other movement disorders
2. Discuss various tools for assessing tardive dyskiensia and demonstrate how to evaluate tardive dyskinesia in a clinical setting
3. Discuss practical considerations on the treatment of tardive dyskinesia with reference to recent evidence-based guidelines

Intended Audience

This activity is intended for industry professionals who work for pharmaceutical and medical device companies.

Hardware and Software Requirements

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher)
5. Adobe Reader to print certificate

Contact Us

MDS Development

MDS Secretariat Liaison

Ken Buesing

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice